Search
Memantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalInitially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million.
Categories: N-methyl-D-aspartate Receptor AntagonistSodium fluoride
go.drugbank.com/drugs/DB09325ApprovedInvestigationalThe use of fluoride in dental practice began in the 1940s. … [L4894] Sodium fluoride's benefits on dental health were first observed in the 1930s, when individuals in communities with fluoridated drinking water showed less tooth decay than those without fluoridated
Mixtures: PREVENT 2 EN 1, E-Z CupsCategories: Compounds used in a research, industrial, or household settingTegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedTegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.
Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamideNilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigational), another tyrosine kinase inhibitor used as a first-line treatment for CML. … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec
ORG-34517
go.drugbank.com/drugs/DB05423InvestigationalIt has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigational[L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778] … Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.
Ritonavir
go.drugbank.com/drugs/DB00503ApprovedInvestigationalAmerican Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for … Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV.
Mixtures: LOPIMUNE ® + RITONAVIR 10 MG - PELLETS EN CÁPSULAS ORALES, LOPINAVIR E RITONAVIR MYLANCategories: Antivirals used in combination for the treatment of HIV infectionsGemcitabine
go.drugbank.com/drugs/DB00441ApprovedInvestigationalIt is approved by the FDA to treat advanced ovarian cancer in combination with [carboplatin], metastatic breast cancer in combination with [paclitaxel], non-small cell lung cancer in combination with [ … [L32950] It is also being investigated in other cancer and tumour types.
Polymyxin B
go.drugbank.com/drugs/DB00781ApprovedInvestigationalVet approvedPolymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line[A176429]. … Polymyxin B was discovered in the 1940s[A176429]. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes[A176426].
Mixtures: H E Buddy Antibiotic Maximum Strength Plus Pain Relief, Bacitracin-N Ointment